API Product   :    Rabeprazole Sodium
CEP   :    -
WCC   :    ?
Therapeutic Use    :    Antacids, antiflatulents and anti-ulcerants; Beta-blocking agents; Systemic antibacterials
Antacids, antiflatulents and anti-ulcerants; Beta-blocking agents; Systemic antibacterials
Originator   :    Eisai
CAS No.    :    117976-89-3
Trade Name.   :    ACIPHEX
Molecular Weight   :    359.44 g/ mol
359.44 g/ mol
Molecular Formula   :    C18H21N3O3S
Aciphex (rabeprazole sodium) is a proton pump inhibitor (PPI) to reduce stomach acid and is used for the treatment of gastroesophageal reflux disease (GERD), duodenal ulcers, and used in combination with antibiotics to treat Helicobacter pylori (H. pylori) bacterial infections in the stomach.
Rabeprazole is a proton pump inhibitor that suppresses gastric acid production in the stomach. It has several medical uses: the management of conditions that involve excess gastric acid production (e.g. Zollinger–Ellison syndrome), conditions that are worsened by gastric acid (e.g. ulcerations of the gastrointestinal tract), and conditions involving prolonged exposure to gastric acid (e.g. symptomatic gastroesophageal reflux disease). Rabeprazole's adverse effects tend to be mild but can be serious, including deficiencies in essential nutrients, rare incidences of liver and bone damage, and dangerous rashes. Rabeprazole can theoretically contribute to numerous drug interactions, mediated both through its metabolic properties and its direct effect on acid in the stomach, though its potential for clinically meaningful drug interactions is low.